Report
Valens Research

IART - Embedded Expectations Analysis - 2020 03 16

 Integra LifeSciences Holdings Corporation (IART:USA) currently trades near corporate averages relative to UAFRS-based (Uniform) Earnings, with a 22.7x Uniform P/E. At these levels, markets are pricing in bearish expectations for the firm, but management is confident about their organic revenue growth, orthopedics business, and revenue guidance

 Specifically, management is confident about their bone cutting segment growth, that they will achieve 5% organic revenue growth for the year, and that they expect to see improvements in the orthopedics business in Q4 and going forward. In addition, they are confident they are tightening their revenue guidance range because of their
year-to-date performance and Q4 expectations, and that they can get back to
mid-single-digit growth for their private labels in the long-term
Underlying
Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings is a medical devices company engaged in the development, manufacturing, and marketing of surgical implants and medical instruments. The company manufactures and sells its products in the following two reportable business segments: Codman Specialty Surgical, which includes technologies in dural repair, ultrasonic tissue ablation, intracranial cranial pressure monitoring, hydrocephalus management, and cranial stabilization systems; and Orthopedics and Tissue Technologies, which focus on addressing soft tissue, nerve, and tendon repairs as well as reconstruction in the hand, wrist, elbow, shoulder, ankle and foot.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch